GLP-1 & GIP Updates and Announcements
Let's walk through the Changes you will find in this updated PocketCard
Quick and Dirty Overview of Changes
- The GLP-1 & GIP Meds PocketCard now includes two distinct versions—one for diabetes and one for weight management with max doses and indications. This side-by-side approach makes it easier to individualize treatment decisions based on a person’s health profile, age, and comorbidities.
- Wegovy 7.2mg High Dose (HD) version was added
- Oral Wegovy, with 25mg max dose added.
- Rybelsus name updated to Oral Ozempic for 1.5 mg, 4 mg, and 9 mg doses.
- Mounjaro now indicated for peds 10-17 yrs
Pharmacology Breakdown and More details
Glucagon-like peptide-1 (GLP-1) receptor agonists and GLP/GIP class of medications have seen significant advancements in the past year and 2026 promises to offer even more advancements.
Semaglutide (Wegovy) for Weight Loss Updates – High Dose & Pediatric Approval
The FDA granted accelerated approval in March 2026 for a high-dose (HD) injectable version of Wegovy at 7.2 mg once weekly. Until now, the highest approved dose for Wegovy—the weight loss formulation of the GLP-1 receptor agonist semaglutide—was 2.4 mg weekly.
Many individuals on the maximum 2.4 mg dose eventually reach a weight loss plateau, prompting researchers to explore whether higher dosing could extend weight reduction. Clinical trials demonstrate that increasing the dose to 7.2 mg weekly can lead to additional weight loss of up to ~20–21% from baseline, representing a meaningful advancement for those needing further support.
As expected, gastrointestinal side effects increase with higher doses, particularly:
- Nausea, Vomiting, Diarrhea, Early satiety
It’s essential to prepare and coach patients proactively by:
- Encouraging slow eating and smaller portions
- Avoiding high-fat, greasy, or very large meals
- Reinforcing hydration
- Considering slower dose escalation when possible
- Normalizing that side effects often improve over time
How Does This Compare to Tirzepatide?
The degree of weight loss with high-dose semaglutide begins to approach that seen with dual GIP/GLP-1 receptor agonists like tirzepatide.
- Tirzepatide (Mounjaro/Zepbound) at higher doses has demonstrated ~15–22% weight loss in clinical trials (depending on population and dose).
- The new 7.2 mg semaglutide dose (~20–21%) now places it in a similar efficacy range, offering another powerful option for patients.
Pediatric Approval Update
Wegovy (2.4 mg) is already approved for adolescents aged 12 and older with obesity, and emerging data continues to support meaningful BMI reduction and cardiometabolic improvements in this population. As higher-dose strategies evolve, careful attention to safety, tolerability, and long-term outcomes in youth remains essential.
Clinical Takeaway 💡
We are entering an era where GLP-1–based therapies are becoming increasingly potent, but with that comes the need for thoughtful dosing, patient education, and ongoing support.
👉 More medication is not always better—
👉 But the right dose for the right person, with the right coaching, can be transformational.
Our Insulin PocketCard Now includes icodec insulin.
Who Might Benefit Most?
Insulin icodec may be especially valuable for:
- People with type 2 diabetes who struggle with taking daily injections.
- Individuals experiencing treatment fatigue or burnout
- Those who would benefit from simplified regimens
- Re-engaging patients hesitant to start insulin
This is where your role as a healthcare professional becomes even more powerful—matching the right therapy to the right person.
Final Thoughts
Insulin icodec represents a transformational step forward in diabetes management. While ongoing evaluation is needed—especially regarding safety and real-world use—this therapy has the potential to reshape how we approach basal insulin. Novo Nordisk plans to launch and release the prefilled FlexTouch® pens in the US in the second half of 2026
As healthcare professionals, staying current with these advancements allows us to:
- Provide evidence-based recommendations
- Support informed decision-making
- And most importantly, meet people where they are
Want to Stay Current on Innovations Like This?
Join us as we break down the latest in diabetes care, guidelines, and emerging therapies— you can bring confidence, clarity, and compassion to your clinical practice by joining our Virtual DiabetesEd Training Conference.
Virtual DiabetesEd Training Conference
Why Should I Attend?
Join national experts including Dr. Diana Isaacs (Cleveland Clinic), Beverly Thomassian (30+ years of experience), and Christine Craig for high-impact, virtual learning—no travel required.
✔ Learn from National Experts — Anywhere
Get the same expert-level instruction you’d receive in person, delivered live to your home or office.
✔ Interactive & Flexible
- Live Q&A and real-time case discussions
- Direct engagement with faculty
- Full session recordings with 1-year access if you can’t attend live
What's Included?
- 19.5 CEs from the 3-day interactive conference + 17+ bonus CEs from 11 on-demand courses. (30+ total CEs are AMA PRA Category 1™, ACPE, ANCC, CDR accredited)
- Less than $15 per credit!
- Expert-led sessions: ADA Standards, medications, insulin therapy, behavior change, CGM, medical nutrition therapy
- Interactive Q&A with expert faculty during live sessions
- 1-year access to all recordings that you can watch on your schedule
- Study material for CDCES and BC-ADM exam prep
Set Yourself Up With Certification Success
Get exam-ready with confidence.
Course credits through AMA PRA Category 1 Credits™, ACPE, ANCC, and CDR!
Full accreditation details are available on the registration page
Our CDCES Boot Camp Online Prep Bundle is a comprehensive, high-impact program built specifically for healthcare professionals preparing for the Certified Diabetes Care and Education Specialist (CDCES) exam who want to level up their clinical knowledge and skills.
This evidence-based study bundle is a comprehensive BC-ADM Boot Camp designed for advanced-level healthcare professionals preparing for the Board Certified in Advanced Diabetes Management (BC-ADM) exam and will also provide you with state-of-the-art information to level up your clinical practice.
Hear What Our Community Has to Say
